Royalty Report: Drugs, Disease, Therapeutic – Collection: 28551


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28551

License Grant
In March 2008 and as amended in August 2008, the Licensee entered into an Agreement to out-License the development rights acquired from Vivoquest in 2005, to the Licensee, a company that  specializes in drug development and marketing. On 4 August 2008, Licensor signed an amendment to the Agreement in which the Licensee assumes responsibility for all development, commercialization and patent cost responsibilities, including all resulting costs, regarding the DOS.
License Property
The Licensor carries out various controls to monitor DOS development progress by the Licensee that include, inter alia, receiving updates from and monitoring FDA publications regarding clinical trials. To the best of the Licensor's knowledge, as of the date of the report, the Licensee has yet to begin carrying out any clinical trial based on DOS technology. Dos technology refers to a compound library including certain compounds (DOS) for the treatment of hepatitis C and other assets.
Field of Use
The rights granted apply to the healthcare industry relating to drug development and marketing.

IPSCIO Record ID: 4271

License Grant
The Israeli Licensor signed an agreement to out-license the DOS program to the Licensee.  The Licensee was granted a license for patent rights and technology relating to the DOS program, and became responsible for all further development and commercialization activities and costs relating to our DOS program.
License Property
The Licensor's drug candidates and technologies are either in preclinical or clinical stages. The lead product candidates, Recombinant Human Erythropoietin (rHuEPO) and SAM-101, are planned for a Phase 2 clinical program and the Diversity Oriented Synthesis, or DOS program.
Field of Use
The Licensee is a specialty pharmaceutical company focused on the discovery, in-licensing, development and commercialization of novel therapeutics for viral infections, including HIV and HCV.

IPSCIO Record ID: 28669

License Grant
The Licensee entered into a License Agreement with the Licensor covering a proprietary compound library, including certain HCV compounds.

The Licensee was granted exclusive worldwide rights to the Licensor's intellectual property and technology in all fields of use.  These assets, cover a compound library including certain compounds, DOS, for the treatment of hepatitis C and other assets.

License Property
The lead molecules that are included in the License are covered by four issued US patents and three pending US patent applications.

As of April 8, 2011, the Company has determined to maintain these patents in the United States only.

Field of Use
The patent applications describe both the structure of the compounds and their use for treating HCV infection.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.